Temozolomide News and Research

RSS

NovoCure initiates newly-diagnosed GBM clinical trial

NovoCure, Ltd., a privately held medical device company focused on developing the Novo-TTF device, a non-invasive portable medical device for the treatment of cancer, announced the completion of a new funding round today. Key investors in this round included Pfizer Inc, Johnson & Johnson Development Corporation and Index Ventures.

29 Sep 2009

Antigenics’ Oncophage cancer vaccine trial starts enrolling patients

Antigenics Inc. (NASDAQ:AGEN) today announced that the Brain Tumor Research Center at the University of California, San Francisco, has begun enrolling patients into a Phase 2 clinical trial of Oncophage (vitespen) in combination with the standard of care - radiation therapy plus Temodar (temozolomide) - for newly diagnosed glioma patients.

13 Aug 2009

Potential new treatment for drug resistant brain tumors

Dr. Karen Newell, Ph. D., the lead researcher for bio technology company Viral Genetics (Pink Sheets: VRAL), will address the 4th Annual Aspen Symposium on Brain Tumor Immuno- and Stem Cell Therapy. Her presentation will highlight the potential for combining chemotherapy with compounds that interfere with the ability of brain tumor cells to generate the energy needed to repair chemotherapy induced DNA damage.

12 Aug 2009

Sensitizing tumor response to cancer treatment

Two forms of skin and brain cancer respond very poorly to chemotherapy and radiation: melanoma and glioblastoma multiforme brain cancer.

5 Aug 2009

Dramatic drop in deaths from most common cancers

The death toll from three of the UK's most common cancers has dropped to its lowest level for almost 40 years* - according to new figures released by Cancer Research UK.

12 Jul 2009

$Hypofractionated stereotactic radiotherapy beneficial for recurrent low-grade glioma$

Hypofractionated stereotactic radiotherapy beneficial for recurrent low-grade glioma

Hypofractionated stereotactic radiotherapy was well-tolerated and improved symptoms in patients with recurrent low-grade glioma, according to researchers from the Kimmel Cancer Center at Jefferson.

22 Apr 2009

Drug therapy for brain tumors shows promise

The combination of two drugs produces a critical improvement in the treatment of certain brain tumours.

8 Mar 2009

European Commission and US FDA approve intravenous formulation of temozolomide

Schering-Plough Corporation (NYSE:SGP) today announced that the European Commission and the US FDA both approved the intravenous (IV) formulation of temozolomide as an alternative to the already approved oral form of the drug.

5 Mar 2009

Brain tumor treatment may increase number of cancer stem-like cells

A new study suggests that the standard treatment for a common brain tumor increases the aggressiveness of surviving cancer cells, possibly leaving patients more vulnerable to tumor recurrence.

5 Mar 2009

Temozolomide sales reach $1 billion

Sales of Temozolomide, an anti-cancer drug developed by Cancer Research UK scientists, have reached $1 billion.

8 Feb 2009

Novel device enhances efficacy of standard chemotherapy

NovoCure Ltd. presented results yesterday evaluating the Novo-TTF device in vitro and in a pilot clinical trial that showed the device enhanced the efficacy of standard chemotherapy (temozolomide) treatment in newly-diagnosed glioblastoma multiforme (GBM) patients.

24 Nov 2008

Genentech submits application to FDA for Avastin in the most aggressive form of brain cancer

Genentech has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin (bevacizumab) as a therapy for people with previously treated glioblastoma. If accepted by the FDA, the application would be considered for an accelerated approval that allows provisional approval of medicines for cancer or other life-threatening diseases based on preliminary evidence suggesting clinical benefit.

3 Nov 2008

Variations in cyclin D1 gene increase susceptibility to malignant melanoma

People who carry a particular genetic variant are at significantly increased risk of developing malignant melanoma, new research shows.

15 Sep 2008

The Cancer Genome Atlas reports first results

The Cancer Genome Atlas (TCGA) has reported results from its first comprehensive study which focused on the deadly brain cancer glioblastoma.

8 Sep 2008

Celldex Therapeutics vaccine may double survival in patients with deadly brain tumors

A vaccine aimed at inducing immunity to the most common and deadly type of brain tumor may stave off recurrence and more than double survival in patients, according to a new study led by researchers in Duke's Preston Robert Tisch Brain Tumor Center.

2 Jun 2008

RTOG study likely treatment option for brain tumor patients like Sen. Kennedy

A Radiation Therapy Oncology Group (RTOG) study which seeks to establish whether high-doses of the chemotherapy drug temozolomide after radiotherapy can improve outcome for patients with newly diagnosed malignant glioma is a possible consideration for Sen. Edward Kennedy (D-Mass.) and other patients with this type of brain tumor.

22 May 2008